Original Articles
Vol. 9 No. 1 (2025)
https://doi.org/10.4081/vsd.2025.10337

Interaction study between cephalexin and omeprazole after oral administration in dogs

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 21 August 2025
119
Views
89
Downloads
15
HTML
Cephalexin, omeprazole, pharmacokinetics, drug interaction, canines

Authors

Martin Pablo Lupi
mlupi@fvet.uba.ar
Department of Pharmacology, Faculty of Veterinary Sciences, University of Buenos Aires, Argentina.
Sabrina Passini
Department of Pharmacology, Faculty of Veterinary Sciences, University of Buenos Aires, Argentina.
Laura Montoya
Department of Pharmacology, Faculty of Veterinary Sciences, University of Buenos Aires, Argentina.
Agustina Monfrinotti
Department of Pharmacology, Faculty of Veterinary Sciences, University of Buenos Aires, Argentina.
Luis Ambros
Department of Pharmacology; CONICET – UBA Institute of Animal Production Research, Faculty of Veterinary Sciences, University of Buenos Aires, Argentina.

Cephalexin, a widely used first-generation cephalosporin antibiotic, is frequently prescribed in veterinary medicine for various bacterial infections in canines. Concurrently, omeprazole, a proton pump inhibitor (PPI), is commonly used to manage gastric ulcers and related conditions. Understanding potential drug interactions is crucial for optimizing therapeutic outcomes. We conducted a study to assess the impact of omeprazole on the disposition of cephalexin in canines. Ten healthy mixed-breed dogs received cephalexin alone and after a 5-day pretreatment with omeprazole. Pharmacokinetic parameters were evaluated using high-pressure liquid chromatography (HPLC) analysis. The mean plasma concentration-time curves showed a relatively slow absorption phase with comparable peak plasma concentrations (Cmax) of 17.32±4.21 μg/mL for cephalexin alone and 16.66±5.26 μg/mL when administered with omeprazole. Similarly, other pharmacokinetic parameters, including area under the plasma concentration-time curve (AUC), elimination half-life (T1/2), absorption half-life (T1/2a), and total body clearance (Cl/F), did not exhibit significant differences between treatments. Our results demonstrate that omeprazole did not significantly alter the pharmacokinetics of cephalexin in canines, allowing for their effective combination without the need for dosage adjustments.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Campbell BG, Rosin E. Effect of food on absorption of cefadroxil and cephalexin in dogs. J Vet Pharmacol Ther 1998;21:418-20. DOI: https://doi.org/10.1046/j.1365-2885.1998.00163.x
2. Carli S, Anfossi P, Villa R, et al. Absorption kinetics and bioavailability of cephalexin in the dog after oral and intramuscular administration. J Vet Pharmacol Ther 1999;22:308-13. DOI: https://doi.org/10.1046/j.1365-2885.1999.00208.x
3. Papich MG, Riviere JE. β-lactam antibiotics: penicillins, cephalosporins, and related drugs. Vet Pharmacol Ther 2018;9:826-57.
4. Toma S, Colombo S, Cornegliani L, et al. Efficacy and tolerability of once-daily cephalexin in canine superficial pyoderma: an open controlled study. J Small Anim Pract 2008;49:384-91. DOI: https://doi.org/10.1111/j.1748-5827.2008.00585.x
5. Silley P, Rudd A, Symington W, et al. Pharmacokinetics of cephalexin in dogs and cats after oral, subcutaneous and intramuscular administration. Vet Rec 1988;122:15-7. DOI: https://doi.org/10.1136/vr.122.1.15
6. Lappin MR, Blondeau J, Boothe D, et al. Antimicrobial use guidelines for treatment of respiratory tract disease in dogs and cats: antimicrobial guidelines working group of the International Society for Companion Animal Infectious Diseases. J Vet Intern Med 2017;31:279-94. DOI: https://doi.org/10.1111/jvim.14627
7. Weese JS, Blondeau JM, Boothe D, et al. Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the International Society for Companion Animal Infectious Diseases. Vet Med Int 2011;2011:263768. DOI: https://doi.org/10.4061/2011/263768
8. Deppermann KM, Lode H, Höffken G, et al. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1989;33:1901-7. DOI: https://doi.org/10.1128/AAC.33.11.1901
9. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet 2010;49:509-33. DOI: https://doi.org/10.2165/11531320-000000000-00000
10. Boothe DM. Gastrointestinal pharmacology. In: Small animal clinical pharmacology and therapeutics. 2nd ed. Saunders; 2012, pp. 672-744.
11. Gaier A, Price J, Grubb L, et al. A prospective, randomized, masked, placebo-controlled crossover study for the effect of 10 mg omeprazole capsules on gastric pH in healthy dogs. J Vet Intern Med 2021;35:887-91. DOI: https://doi.org/10.1111/jvim.16061
12. Marks SL, Kook PH, Papich MG, et al. ACVIM consensus statement: support for rational administration of gastrointestinal protectants to dogs and cats. J Vet Intern Med 2018;32:1823-40. DOI: https://doi.org/10.1111/jvim.15337
13. Tolbert MK. Gastroprotective therapy. Vet Clin Small Anim Pract 2020;51:33-41. DOI: https://doi.org/10.1016/j.cvsm.2020.09.001
14. Wedemeyer RS, Blume H. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Drug Saf 2014;37:201-11. DOI: https://doi.org/10.1007/s40264-014-0144-0
15. Grube S, Langguth P. Excipients as modulators of drug-carrier mediated absorption in the intestine. In: Mashkevich BO (Ed.), Drug Deliv Res Adv 2007, Chapter 3.
16. Madaras-Kelly K, Michas P, George M, et al. A randomized crossover study investigating the influence of ranitidine or omeprazole on the pharmacokinetics of cephalexin monohydrate. J Clin Pharmacol 2004;44:1391-7. DOI: https://doi.org/10.1177/0091270004269558
17. Al-Said MS, Al-Khamis KI, Niazy EM, et al. Bioequivalence evaluation of two brands of cefuroxime 500 mg tablets (Cefuzime and Zinnat) in healthy human volunteers. Biopharm Drug Dispos 2000;21:205-10. DOI: https://doi.org/10.1002/bdd.237
18. Gibaldi M, Perrier D. Farmacocinética. Barcelona, España: Editorial Reverté S.A.; 1982, pp. 182-184. DOI: https://doi.org/10.1201/b14095
19. Yamahoka K, Nakagawa T, Uno T. Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharm Biopharm 1978;6:165-75. DOI: https://doi.org/10.1007/BF01117450
20. Prados AP, Ambros L, Montoya L, et al. Chronopharmacological study of cephalexin in dogs. Chronobiol Int 2007;24:161-70. DOI: https://doi.org/10.1080/07420520601089547
21. Prados AP, Kreil V, Albarellos G, et al. Metoclopramide modifies oral cephalexin pharmacokinetics in dogs. J Vet Pharmacol Ther 2007;30:127-31. DOI: https://doi.org/10.1111/j.1365-2885.2007.00831.x
22. Faruquee CF, Ullah A, Azad MAK, et al. Interaction study between levofloxacin and omeprazole using urinary pharmacokinetic data. Pak J Pharm Sci 2010;23:143-8.

Supporting Agencies

This study was funded by the Secretaría de Ciencia y Técnica, Universidad de Buenos Aires Research Project UBACyT. Grant number: 20020220200090BA.

How to Cite



Interaction study between cephalexin and omeprazole after oral administration in dogs. (2025). Veterinary Science Development, 9(1). https://doi.org/10.4081/vsd.2025.10337
Copyright (c) 2025 Martin Pablo Lupi, Sabrina Passini, Laura Montoya, Agustina Monfrinotti, Luis Ambros Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.